Digital Health Solution for COPD
Researchers from Weill Cornell Medical College and New York-Presbyterian Hospital launched a new study that will use a Bluetooth enabled version of the Flyp Nebulizer from Welllinks. This device will include a suite of connected diagnostic tools, including spirometry and pulse-oximetry, to provide a digital health solution for people with COPD. The devices communicate with an app on the user’s phone to send data to a HIPAA secure cloud environment. The data displays in dashboards and reports that will help clinicians care for their patients. “Our hope is that with better home monitoring, we can detect exacerbations, understand medication compliance and usage, and adjust therapy to prevent clinical worsening,” said primary investigator Dr. Brian D. Gelbman. “This could be immensely useful in the care of COPD patients, many of whom are homebound and have difficulty traveling to office visits, especially during the COVID-19 pandemic.” Read More
Inhaled COVID-19 Treatment Study Reaches 55% Enrollment
According to Ampio Pharmaceuticals, Inc., the Phase 1 clinical trial of its inhalation therapy for patients with COVID-19 has reached 55% enrollment. “Our experience using inhaled Ampion to treat patients with COVID-19 continues to trend positively, showing no serious drug-related adverse effects,” said Michael Roshon, MD, PhD, chief of medical staff at Penrose-St. Francis Health Services in Colorado Springs, CO, where the study is being conducted. “We look forward to seeing the full results of the study as therapeutics for COVID-19 continue to be in high demand.” In vitro studies have shown Ampion interrupts the cytokine storm, which is directly associated with more severe symptoms of COVID-19. Read More
United Therapeutics Joins Genentech and Boehringer Ingelheim as PFF Registry Sponsor
United Therapeutics has signed on as a sponsor of the Pulmonary Fibrosis Foundation’s PFF Registry. This sponsorship will further assist researchers working to find new therapies for patients suffering from pulmonary fibrosis and secondary pulmonary fibrosis for whom no FDA-approved therapies currently exist. United Therapeutics joins Genentech and Boehringer Ingelheim at the highest levels of sponsorship for the Registry. Launched in 2016, the PFF Registry tracks clinical data, blood samples, and patient-reported outcomes among pulmonary fibrosis patients across the country. To date, nearly 40 studies have used data from the Registry. Read More
Jubilant Therapeutics, Wistar Institute Team Up to Study PAD4 Inhibitors in COVID-19
Jubilant Therapeutics Inc. entered into a collaboration with The Wistar Institute to evaluate the company’s Peptidyl Arginine Deiminase 4 (PAD4) inhibitors to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms. “Even with COVID-19 vaccines on the horizon, we know its wrath will persist for some time to come, and the need to reduce its death toll remains critical,” said Jubilant Therapeutics President and CEO Syed Kazmi. “Beyond COVID-19, understanding the potential of PAD4 inhibitors to address aberrant NET formation will be important due to their role in the pathogenesis of many disease states beyond viral infections.” Read More
Email newsroom@aarc.org with questions or comments, we’d love to hear from you.
